Erin Boh is a Dermatology physician affiliated with Tulane University. OpenAlex indexes 102 publications with 1,943 citations (h-index 20).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1430 Tulane Ave
Tb36
New Orleans, LA 701122632
Telephone
504-988-5114Registry record last updated 11 Aug 2011.
Industry payments
26 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year202513 payments$21,268openpaymentsdata.cms.gov ↗
- GENZYME CORPORATIONProgram year20256 payments
- Ortho Dermatologics, a division of Bausch Health US, LLCProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
28.4%Retinoid6.4%Bexarotene91%Targretin9%Part D<11 patientsFolate Analog Metabolic Inhibitor5.9%Methotrexate94%Methotrexate Sodium6%Part D<11 patients+ 10 more classes in this area
Anti-infectives
13.8%Azole Antifungal7.4%Ketoconazole82%Fluconazole18%Part D≥78 patientsSulfone2.2%Dapsone100%Part D≥22 patients+ 4 more classes in this area
Dermatology
9.5%Corticosteroid5.1%Triamcinolone Acetonide100%Part D≥86 patientsInterleukin-4 Receptor alpha Antagonist2.2%Dupixent Syringe100%Part D<11 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A Review of the Safety and Efficacy of Deucravacitinib for Plaque Psoriasis: An Expert Consensus Panel
Journal of Drugs in Dermatology
2025 - Cutaneous T cell lymphoma arising in patients treated with dupilumab: A case series of 18 patients
Journal of the American Academy of Dermatology
2024 - Utility of hydroxychloroquine laboratory monitoring in dermatologic and rheumatologic patients
Archives of Dermatological Research
2024 - Healthcare Provider Experience in Diagnosing and Treating Cutaneous T-Cell Lymphoma
Dermatology and Therapy
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Erik Castle, MD
Tulane University
John Schieffelin, MD
Tulane University
Thierry Lejemtel, MD
Tulane University
Robert Hendel, MD
Tulane University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”